Osteosarcoma-Pipeline Review, H1 2015

Osteosarcoma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6549IDB
  • |
  • Pages: 137
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Osteosarcoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Osteosarcoma-Pipeline Review, H1 2015', provides an overview of the Osteosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Osteosarcoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Osteosarcoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Osteosarcoma Overview 9

Therapeutics Development 10

Pipeline Products for Osteosarcoma-Overview 10

Pipeline Products for Osteosarcoma-Comparative Analysis 11

Osteosarcoma-Therapeutics under Development by Companies 12

Osteosarcoma-Therapeutics under Investigation by Universities/Institutes 13

Osteosarcoma-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Osteosarcoma-Products under Development by Companies 16

Osteosarcoma-Products under Investigation by Universities/Institutes 17

Osteosarcoma-Companies Involved in Therapeutics Development 18

Advaxis, Inc. 18

Amgen Inc. 19

Bayer AG 20

Bellicum Pharmaceuticals, Inc. 21

Eleison Pharmaceuticals, Inc. 22

Exelixis, Inc. 23

Isofol Medical AB 24

Merck & Co., Inc. 25

Merrimack Pharmaceuticals, Inc. 26

Neusentis 27

Novartis AG 28

Sutro Biopharma, Inc. 29

Osteosarcoma-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

ADXS-HER2-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

alendronate sodium + HPMA + TNP-470-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

AM-7209-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

BL-1249-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

cabozantinib s-malate-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Cell Therapy for GD2 Expressing Solid Tumors-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Cell Therapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

celyvir-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

cisplatin-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

everolimus-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

irinotecan sucrosofate liposomal-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ISOMC-091-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

LLL-12-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

MBC-11-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Monoclonal Antibody to Inhibit GD2 for Oncology-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Monoclonal Antibody to Target GD2 for Osteosarcoma-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

pazopanib hydrochloride-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

pembrolizumab-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Peptide to Target COX-2 and MAS-GPCR for Oncology-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

radium Ra 223 dichloride-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules to Inhibit CaMKII for Osteosarcoma-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Vaccine for Osteosarcoma-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Osteosarcoma-Recent Pipeline Updates 88

Osteosarcoma-Dormant Projects 130

Osteosarcoma-Discontinued Products 131

Osteosarcoma-Product Development Milestones 132

Featured News & Press Releases 132

Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting 132

Oct 30, 2014: Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study 132

May 27, 2014: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma 133

Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch 133

Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma 135

Appendix 136

Methodology 136

Coverage 136

Secondary Research 136

Primary Research 136

Expert Panel Validation 136

Contact Us 136

Disclaimer 137

List of Tables

Number of Products under Development for Osteosarcoma, H1 2015 10

Number of Products under Development for Osteosarcoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Osteosarcoma-Pipeline by Advaxis, Inc., H1 2015 18

Osteosarcoma-Pipeline by Amgen Inc., H1 2015 19

Osteosarcoma-Pipeline by Bayer AG, H1 2015 20

Osteosarcoma-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 21

Osteosarcoma-Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 22

Osteosarcoma-Pipeline by Exelixis, Inc., H1 2015 23

Osteosarcoma-Pipeline by Isofol Medical AB, H1 2015 24

Osteosarcoma-Pipeline by Merck & Co., Inc., H1 2015 25

Osteosarcoma-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 26

Osteosarcoma-Pipeline by Neusentis, H1 2015 27

Osteosarcoma-Pipeline by Novartis AG, H1 2015 28

Osteosarcoma-Pipeline by Sutro Biopharma, Inc., H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Assessment by Combination Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 36

Number of Products by Stage and Route of Administration, H1 2015 38

Number of Products by Stage and Molecule Type, H1 2015 40

Osteosarcoma Therapeutics-Recent Pipeline Updates, H1 2015 88

Osteosarcoma-Dormant Projects, H1 2015 130

Osteosarcoma-Discontinued Products, H1 2015 131

List of Figures

Number of Products under Development for Osteosarcoma, H1 2015 10

Number of Products under Development for Osteosarcoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38

Number of Products by Top 10 Molecule Types, H1 2015 39

Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Advaxis, Inc.

Amgen Inc.

Bayer AG

Bellicum Pharmaceuticals, Inc.

Eleison Pharmaceuticals, Inc.

Exelixis, Inc.

Isofol Medical AB

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.


Novartis AG

Sutro Biopharma, Inc.

Osteosarcoma Therapeutic Products under Development, Key Players in Osteosarcoma Therapeutics, Osteosarcoma Pipeline Overview, Osteosarcoma Pipeline, Osteosarcoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 136180
Site License
USD 4000 INR 272360
Corporate User License
USD 6000 INR 408540



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com